Prime Medicine (PRME) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Prime Medicine (PRME) has outperformed Valneva (VALN) over the past year, losing 44.5% versus a loss of 48.4%. Prime Medicine is the larger company by market cap ($649.3 million vs $539.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRME | VALN |
|---|---|---|
| Share price | $3.58 | $5.69 |
| Market cap | $649.33M | $539.55M |
| 1-day change | -8.21% | -3.07% |
| YTD return | +3.17% | -35.49% |
| 1-year return | -44.50% | -48.41% |
| 5-year return | — | -79.71% |
| Forward P/E | — | 4.78 |
| EPS (TTM) | $-1.07 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.65 | $12.18 |
| 52-week low | $2.67 | $4.75 |
| Distance from 52-week high | -46.17% | -53.28% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +98.60% | +115.29% |
| Average volume | 3.36M | 78.17K |
| Shares outstanding | 181.38M | 94.82M |
| Employees | 146 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Prime Medicine
PRME stock →Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 146 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
PRME vs VALN FAQ
Which is bigger, Prime Medicine or Valneva?
Prime Medicine (PRME) is larger, with a market capitalization of $649.33M compared with $539.55M for Valneva (VALN).
Which stock has performed better over the past year, PRME or VALN?
PRME returned -44.50% over the past 12 months, compared with -48.41% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are Prime Medicine and Valneva in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.